PTGS2 and neoplasm: Celecoxib treatment led to a dramatic reduction in both total (CD31+) and α-SMA+ vessels in NIH3T3-vGPCR tumors (Fig 7A, left panel), indicating that COX-2 inhibition greatly compromised vGPCR tumor angiogenicity.